US2016151351A1PendingUtilityA1
Non-abusable pharmaceutical composition comprising opioids
Est. expiryDec 4, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Anders Pettersson
A61P 25/00A61P 29/00A61P 25/36A61P 25/04A61K 31/485A61K 9/5084A61K 9/1676A61K 9/2077A61K 9/167A61K 9/006A61K 31/4468A61K 9/14
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating a subject in need thereof comprising, administering a particulate transmucosal pharmaceutical composition comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic, wherein both of said opioid analgesic and said opioid antagonist are delivered transmucosally, wherein the opioid analgesic is selected from fentanyl, alfentanil, sufentanil, remifentanil and buprenorphine, and the opioid antagonist is selected from nalmefene, methylnaltrexone, naltrexone and naloxone.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.